EMEA-003051-PIP01-21
Key facts
| Active substance |
Depemokimab
|
| Therapeutic area |
Pneumology-allergology
|
| Decision number |
P/0417/2021
|
| PIP number |
EMEA-003051-PIP01-21
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of nasal polyposis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
GlaxoSmithKline Trading Services Limited
E-mail: eu.paediatric-plans@gsk.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|